



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/996,023	11/16/2001	Peter Madsen	6258.200-US

CONFIRMATION NO. 2060

## FORMALITIES LETTER



\*OC000000007185001\*

Reza Green, Esq.  
Novo Nordisk of North America, Inc.  
Suite 6400  
405 Lexington Avenue  
New York, NY 10174-6401

Date Mailed: 12/12/2001

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.


*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

03/07/2002 SHINASS1 00000003 141447 09996023

01 FC:105 130.00 CH



#3

Attorney Docket No.: 6258.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Madsen et al

Serial No.: 09/996,023

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

Confirmation No: 2060

For: Glucagon Antagonists/Inverse Agonists

**RESPONSE TO NOTICE TO FILE MISSING PARTS**

Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Notice to File Missing Parts dated December 12, 2001 (a copy thereof is attached hereto), Applicants submit the Combined Declaration and Power of Attorney signed and dated by Applicants for the above-captioned application.

Applicants also enclose a certified copy of Danish application no. PA 2000 01731 filed November 17, 2000, priority of which is claimed under 35 U.S.C. 119.

Please charge the required fee, estimated to be \$130.00, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,


Date: February 20, 2002

Richard W. Bork  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6258.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lau et al

Serial No.: 09/996,023

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

Confirmation No: 2060

For: Glucagon Antagonists/Inverse Agonists

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Petition and Fee For Extension of Time (in duplicate)
2. Response to Notice to File Missing Parts (in duplicate)
3. Copy of Notice to File Missing Parts
4. Executed Combined Declaration and Power of Attorney
5. Certified copy of Priority Application(s)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on February 20, 2002.

Sylvia Gonzalez  
(name of person mailing paper)

  
(signature of person mailing paper)